PATENT CLAIM ANALYSIS

Application Number: 15764730
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "004900"]

Abstract:
The disclosure is related to a method of treating a disorder, such as obesity or a condition associated with obesity, such as hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist.

Claim (Index 28):
The method of any of the preceding claims, wherein the agonist comprises the sequence 001554C (SEQ\u2003ID\u2003NO:\u20031) Ac-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   001555C (SEQ\u2003ID\u2003NO:\u20032) Ac-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   001556C (SEQ\u2003ID\u2003NO:\u20033) Ac-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   001574C: (SEQ\u2003ID\u2003NO:\u20034) Ac-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   001576C: (SEQ\u2003ID\u2003NO:\u20035) Ac-Arg-(Glu-Gln-D-Phe-Arg-Trp-Apr)-NH 2   (SEQ\u2003ID\u2003NO:\u20036) Ac-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u20037) H-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u20038) H-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u20039) Ac-D-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200310) H-D-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200311) Ac-D-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200312) H-D-Arg-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200313) Ac-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200314) Ac-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200315) H-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200316) H-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200317) Ac-D-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200318) H-D-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200319) Ac-D-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200320) H-D-Lys-(hCys-Asn-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200321) Ac-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200322) H-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200323) H-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200324) Ac-D-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200325) H-D-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200326) Ac-D-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200327) H-D-Arg-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200328) Ac-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200329) Ac-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200330) H-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200331) H-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200332) Ac-D-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200333) H-D-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200334) Ac-D-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200335) H-D-Lys-(hCys-Gln-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200336) Ac-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200337) H-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200338) H-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200339) Ac-D-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200340) H-D-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200341) Ac-D-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200342) H-D-Arg-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200343) Ac-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200344) Ac-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200345) H-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200346) H-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200347) Ac-D-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200348) H-D-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200349) Ac-D-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200350) H-D-Lys-(hCys-Ser-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200351) Ac-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200352) H-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200353) H-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200354) Ac-D-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200355) H-D-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200356) Ac-D-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200357) H-D-Arg-(hCys-Thr-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200358) Ac-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200359) Ac-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200360) H-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200361) H-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-OH   (SEQ\u2003ID\u2003NO:\u200362) Ac-D-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200363) H-D-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2   (SEQ\u2003ID\u2003NO:\u200364) Ac-D-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2 or   (SEQ\u2003ID\u2003NO:\u200365) H-D-Lys-(hCys-Thr-D-Phe-Arg-Trp-Pen)-NH 2 .

Metadata:
- Claim Count in Document: 1.0
- Percentile: 90.0
- Lexical Diversity: 1.31034
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14775916', '14800627', '15442229', '13057966', '13074565']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8183092868113458
- 35 USC 102 Novelty (BERT): 0.5537121957428204
- Combined Prediction Score: 0.7918495777044933
- Mean Citation Score: 408.489952
- Max Citation Score: 437.57434000000006
- Similarity Product: 315.5750622552205

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test